PFIZER INC
CIK: 0000078003Latest portfolio: $236.5M · Q4 2025
Holdings
18
Total Value
$236.5M
New Positions
0
Closed Positions
3
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | ORICORIC PHARMACEUTICALS INC | 5,376,344 | $44.0M | 18.60% | — | |
| 2 | ARVNARVINAS INC | 3,457,815 | $41.0M | 17.34% | — | |
| 3 | CELCCELCUITY INC | 349,406 | $34.8M | 14.74% | — | |
| 4 | WVEWAVE LIFE SCIENCES LTD | 1,875,000 | $31.9M | 13.48% | — | |
| 5 | ALLOALLOGENE THERAPEUTICS INC | 22,032,040 | $30.2M | 12.76% | — | |
| 6 | ZURAZURA BIO LTD | 2,970,022 | $15.6M | 6.58% | — | |
| 7 | PYXSPYXIS ONCOLOGY INC | 7,032,770 | $8.1M | 3.42% | — | |
| 8 | CRBUCARIBOU BIOSCIENCES INC | 4,690,431 | $7.5M | 3.15% | — | |
| 9 | CRDFCARDIFF ONCOLOGY INC | 2,411,575 | $6.8M | 2.87% | — | |
| 10 | BHVNBIOHAVEN LTD | 505,645 | $5.7M | 2.41% | — | |
| 11 | SPROSPERO THERAPEUTICS INC | 2,362,348 | $5.5M | 2.33% | — | |
| 12 | NXTCNEXTCURE INC | 157,646 | $2.2M | 0.95% | — | |
| 13 | ZNTLZENTALIS PHARMACEUTICALS INC | 953,834 | $1.3M | 0.54% | — | |
| 14 | QTTBQ32 BIO INC | 277,777 | $922K | 0.39% | — | |
| 15 | ANTXAN2 THERAPEUTICS INC | 715,295 | $815K | 0.34% | — | |
| 16 | BOLTBOLT BIOTHERAPEUTICS INC | 31,305 | $171K | 0.07% | — | |
| 17 | DNAGINKGO BIOWORKS HOLDINGS INC | 2,928 | $24K | 0.01% | — | |
| 18 | SENS1GBPSENSEONICS HLDGS INC | 2,171 | $11K | 0.00% | -41,255 |
Quarterly Changes
New Positions
No new positions this quarter
Increased Positions
No increased positions
Decreased Positions
| Name | Shares | Change |
|---|---|---|
| SENS1GBP | 2K | -41255 |
Sector Breakdown
Healthcare0.1% ($4.397841009348494e+59T)
Unknown0.0% ($11K)
Filing History
Fund Information
PFIZER INC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $236.5M across 18 holdings. The largest position is ORIC PHARMACEUTICALS INC (ORIC), representing 18.6% of the portfolio. Compared to the previous quarter, the fund opened 0 new positions and closed 3 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.